



MITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Peter STREHLKE et al.

Serial No.: 10/078,530

Group Art Unit: 1625

Filed: February 21, 2002

Examiner: TBA

For: QUINOLINE, ISOQUINOLINE AND PHTHALAZINE DERIVATIVES AS ANTAGONISTS OF THE GONADOTROPIN-RELEASING HORMONE

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

ington,	D. C. 20	oner for Patents 0231 ERIALS	I hardy early has a series as first that have enveloped addressed for communication of primaries fractions. Washington, D.C. 2023 for the first that the series washington, D.C. 2023 for the filament of the				
Appli	cant(s) l	hereby disclose the infe	ormation listed in the attached form PTO-1449.				
	-	s of materials listed but ; see 37 C.F.R. §	t not attached were cited in parent application Serial 1.98(d).				
	Repor refere	t dated; receipt	at not attached were cited in an International Search to f the International Search Report and copies of the PCT International Division of the U.S. PTO in ailed				
ADDI	TIONA	L INFORMATION					
	Also refere	attached is a copy an nces.	Internationa	l Search Rep	port and U.S.	equivalent	
LANC	GUAGE	2					
⊠	All lis	sted materials are in the	English lan	guage; see 37	C.F.R. § 1.98		
	Non-H	English language refere	ences:				
	comm	The reference(s): tercial data bases to co		_	age is (are) in s): , resp	dicated by ectively.	
	□ provid	(An) English-langua led.	ge translatio	n(s) of the re	eferences:	is (are)	
	П	A commercial Engli	sh-language	abstract of re	ference(s)	is (are)	

	provid	ed.	
		An English-language search report or an equivalent paper for office translated into English in pertinent part in connectpart foreign application, is provided indicating the relevance (s).	ection with a
<u>FEES</u>			
⊠	No fee	is required for this Information Disclosure Statement because	e:
	within	This Information Disclosure Statement is being filed within filing date of a national application (other than a CPA) unde 3 months of the date of entry of the national stage under ational application;	r § 1.53(d) or
	⊠ a first a	This Information Disclosure Statement is being filed before action on the merits;	the mailing of
	notice	This Information Disclosure Statement is being filed after a crits but before the mailing date of any of a final action und of allowance under § 1.311, or an action that closes prosestion, and is accompanied by a certification below.	ler § 1.113, a
		This Information Disclosure Statement is filed under 37 C.I	F.R. § 1.97(i).
	A fee i	is required for this Information Disclosure Statement:	
	notice	This Information Disclosure Statement is being filed after a crits but before the mailing date of any of a final action under a fallowance under § 1.311 or an action that closes prosecutive panied by the fee set forth in §1.17(p).	ler § 1.113, a
	prosec	This Information Disclosure Statement is being filed after the nal rejection or a notice of allowance under § 1.311 or an activation, but before the payment of the issue fee, and is accomforth in § 1.17(p) and a certification below.	on that closes
CERT	IFICAT	<u> ION</u>	
	cited in	tem of information contained in this Information Disclosure Son a communication from a foreign patent office in a count ation not more than three months prior to the filing of this son	erpart foreign
0	cited in application	m of information contained in this Information Disclosure Son a communication from a foreign patent office in a count ation and, to the knowledge of the undersigned, having mady, no such item was known to any individual designated), more than three months prior to the filing of the	erpart foreign de reasonable in 37 CFR §

SCH 1805

DEPOSIT ACCOUNT

If a fee is due, attached is a check in the amount of \$_____. However, the Commissioner is hereby authorized to charge fees under 37 CFR § 1.16 and § 1.17 which may be required to facilitate this filing, or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Harry B. Shubin, Reg. No. 32,004 Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C. Arlington Courthouse Plaza l 2200 Clarendon Blvd. Suite 1400 Arlington, Virginia 22201 Telephone: (703) 243-6333

Facsimile: (703) 243-6410

FILED: November 14, 2002

STAMBORM & 200Z 8 1 VON Please type 391

Approved for use through 17012/APMP U.S. Patent and Trademark Office: U.S. DEPARTMENT OF L.C. of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB con Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of

Complete if Known					
Application Number	0/078,530				
Filing Date	February 21, 2002				
First Named Inventor	STREHLKE et al.				
Group Art Unit	1625				
Examiner Name	ТВА				
Attorney Docket Number	SCH 1805				

		-	U.S. PATENT DOCUM	MENTS	
Examiner Initials *	Cite No.	U.S. Patent Document Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	5,807,869	Furuya et al.	9/15/98	
	AB	6,150,522	Goulet et al.	11/21/00	
	AC	6,087,503	Furuya et al.	7/11/00	

				FOREIG	N PATENT DOCU	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document			Name of Patentee	Date of Publication of	Pages, Columns, Lines, Where Relevant	
		Office ³	Number⁴	Kind Code ⁵ (if known)	or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T ₆
	AD	Wipo	97/14682			4/24/97		
	AE	Wipo	97/44041			11/27/97		
								
	<u> </u>							
		 						
		 	<u> </u>					
	ļ	1						

Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

¹ Unique citation designation number: 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark hee if English language Translation is attached.